Kirin Looking to Develop Lactococcus Lactis-Based COVID-19 Drug

August 10, 2022
Kirin Holdings said on August 8 that the Japan Agency for Medical Research and Development (AMED) will provide funding for its research on the suppression of coronavirus proliferation by using the company’s proprietary “ Lactococcus lactis strain Plasma.” “This is...read more